These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5809744)

  • 21. Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury.
    Liu Y; Hirooka K; Nishiyama A; Lei B; Nakamura T; Itano T; Fujita T; Zhang J; Shiraga F
    Exp Eye Res; 2012 Mar; 96(1):116-23. PubMed ID: 22200488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitation of isoproterenol-induced myocardial necrosis with 3H-tetracycline.
    Ryan CF; Athari-Nejad A; Holcslaw TL
    Res Commun Chem Pathol Pharmacol; 1979 Sep; 25(3):489-501. PubMed ID: 504787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.
    Cutler GB; Sauer MA; Loriaux DL
    J Pharmacol Exp Ther; 1979 Apr; 209(1):144-6. PubMed ID: 430374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of antialdosterone compounds (spirolactones) on the antinatruresis of the upright position in pregnancy.
    LONGO LD; ASSALI NS
    Surg Gynecol Obstet; 1960 Jun; 110():673-5. PubMed ID: 14418164
    [No Abstract]   [Full Text] [Related]  

  • 25. Opposing effects of deoxycorticosterone and spironolactone on isoprenaline-induced myocardial infarction.
    Wexler BC
    Cardiovasc Res; 1979 Feb; 13(2):119-26. PubMed ID: 466659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
    Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
    Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of an aldosterone-antagonist (SC-8109) on radio-sodium (Na22) metabolism in rats with hypothalamic lesions.
    LUPULESCU A; NICOLESCU-CATARGIA ; NEACSUC
    Acta Biol Med Ger; 1961; 6():482-90. PubMed ID: 14467462
    [No Abstract]   [Full Text] [Related]  

  • 28. An analysis of the reduction by creatinol O-phosphate of the myocardial lesions evoked by isoprenaline in the rat.
    Godfraind T; Sturbois X
    Arzneimittelforschung; 1979; 29(9a):1457-64. PubMed ID: 575492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of agents that affect aldosterone action.
    Tamargo J; Solini A; Ruilope LM
    Semin Nephrol; 2014 May; 34(3):285-306. PubMed ID: 25016400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukocyte collagenolytic activity in normal and hydrazinophthalazine-treated rats during isoprenaline-induced cardiomyopathy.
    Drózdz M; Piwowarczyk B; Olczyk K; Wieczorek M; Wróblewska-Adamek I
    Exp Pathol; 1983; 23(4):253-8. PubMed ID: 6307734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
    Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
    Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of refractory edema by spirolactones (antialdosterone). Clinical and biological study].
    VESIN P; BLANPIN O; JULIEN C; GIBOUDEAU J; RENAULT H; CATTAN R
    Bull Mem Soc Med Hop Paris; 1959 Oct 9-23; 75():826-40. PubMed ID: 13841977
    [No Abstract]   [Full Text] [Related]  

  • 33. Protection of rats from isoproterenol induced myocardial necrosis by trolnitrate phosphate (Metamine).
    Scriabine A; Stebbins RB
    Experientia; 1966 Feb; 22(2):106-7. PubMed ID: 5927953
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes.
    Mayyas F; Alzoubi KH; Bonyan R
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27992114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocardial necrosis in the rat: a comparison between isoprenaline, orciprenaline, salbutamol and terbutaline.
    Magnusson G; Hansson E
    Cardiology; 1973; 58(3):174-80. PubMed ID: 4773536
    [No Abstract]   [Full Text] [Related]  

  • 36. [A study of the natriuretic action of an antagonist of aldosterone: spirolactone SC 9420 (aldactone)].
    VEYRAT R; ENGEL E; DUCOMMUN P; MULLER AF
    Schweiz Med Wochenschr; 1960 Apr; 90():494-7. PubMed ID: 13842023
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition.
    Cai J; Chen X; Chen X; Chen L; Zheng G; Zhou H; Zhou X
    Cell Physiol Biochem; 2017; 41(3):1167-1178. PubMed ID: 28245473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
    Casals-Stenzel J; Buse M; Wambach G; Losert W
    Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
    Rocha R; Martin-Berger CL; Yang P; Scherrer R; Delyani J; McMahon E
    Endocrinology; 2002 Dec; 143(12):4828-36. PubMed ID: 12446610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart.
    Barbato JC; Rashid S; Mulrow PJ; Shapiro JI; Franco-Saenz R
    Hypertension; 2004 Nov; 44(5):751-7. PubMed ID: 15466666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.